KAPA — Kairos Pharma, LTD.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1962011 ·
Last close
$0.40
Market Cap
$1.35M
52W High
$7.28
52W Low
$0.38
ADV30
345,537
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,009,000 | -1,984,000 | 4,370,000 | 3,125,000 | 495,000 |
| Jun 2026 | 0 | — | -1,417,000 | -1,388,000 | 4,456,000 | 2,626,000 | 265,000 |
| Mar 2026 | 0 | — | -1,690,000 | -1,654,000 | 5,744,000 | 3,675,000 | 431,000 |
| Dec 2025 | 0 | — | -1,415,000 | -1,365,000 | 6,540,000 | 4,491,000 | 199,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,970,000
Investing CF
—
Financing CF
$3,562,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.29
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-17,304,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-5,870,000
Pretax Income TTM
$-5,805,000
Interest Exp TTM
$0
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -5,572,000 | -5,447,000 | 6,540,000 | 199,000 | 6,341,000 | -3,441,000 |
| Dec 2024 | 0 | -2,343,000 | -2,603,000 | 5,768,000 | 992,000 | 4,776,000 | -3,955,000 |
| Dec 2023 | 0 | -1,714,000 | -1,812,000 | 965,000 | 3,043,000 | -2,078,000 | 81,000 |
| Dec 2022 | 0 | -571,000 | -1,050,000 | 1,036,000 | 2,215,000 | -1,179,000 | -353,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-5,805,000
OpCashFlow TTM
—
Assets (Latest)
$4,456,000
Forward EPS
$-4.69
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GNPX | Genprex, Inc. | $1.37M | $1.67 | — |
| AGNPF | Grey Matters Health Inc. | $1.30M | $0.24 | — |
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
| HCWB | HCW Biologics Inc. | $1.43M | $0.78 | — |
| ISCO | International Stem Cell CORP | $1.28M | $0.16 | — |
News headlines (Yahoo Finance, 1h cache)
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
2026-11-05 14:15 · Yahoo
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
2026-11-03 16:45 · Yahoo
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
2026-10-22 13:16 · Yahoo
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
2026-10-06 11:30 · Yahoo
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
2026-09-23 12:00 · Yahoo
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 12:00 · Yahoo
Kairos Pharma Announces 1-for-7 Reverse Stock Split
2026-08-21 20:30 · Yahoo
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
2026-07-22 12:35 · Yahoo
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever
2026-07-15 12:39 · Yahoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
2026-05-13 09:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.